Increased orocecal transit time in patients with nonalcoholic fatty liver disease

Simple item page
dc.contributor.authorSoza, A
dc.contributor.authorRiquelme, A
dc.contributor.authorGonzález, R
dc.contributor.authorAlvarez, M
dc.contributor.authorPérez-Ayuso, RM
dc.contributor.authorGlasinovic, JC
dc.contributor.authorArrese, M
dc.date.accessioned2025-01-21T01:06:56Z
dc.date.available2025-01-21T01:06:56Z
dc.date.issued2005
dc.description.abstractIntestinal bacterial overgrowth (IBO) has been suggested to play a pathogenic role in patients with nonalcoholic fatty liver disease (NAFLD). Delayed intestinal transit may contribute to IBO development. Ten nondiabetic patients with NAFLD and abnormal liver enzymes were recruited. Ten healthy individuals, matched by sex, age, and body mass index, were used as controls. Orocecal transit time (OCTT) was measured by the lactulose breath test. Anti-endotoxin core antibodies (EndoCAb) were determined. The effect of oral norfloxacin (400 mg BID during 2 weeks) on liver enzymes, lactulose breath test, and EndoCAb was also studied. NAFLD patients had higher basal breathed H, and prolonged OCTT compared to controls (127 +/- 61 vs. 57 +/- 23 min, respectively; P=0.0037). EndoCAb titers were similar in NAFLD patients and controls. Norfloxacin administration had no effect on ALT levels, lactulose breath test, or EndoCAb titers in patients with NAFLD. The present data show evidence of deranged intestinal motility in nondiabetic patients with NAFLD and support the hypothesis that NAFLD could be linked to endotoxin-induced liver damage of intestinal origin.
dc.fuente.origenWOS
dc.identifier.doi10.1007/s10620-005-2720-8
dc.identifier.eissn1573-2568
dc.identifier.issn0163-2116
dc.identifier.urihttps://doi.org/10.1007/s10620-005-2720-8
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/96247
dc.identifier.wosidWOS:000229801500027
dc.issue.numero6
dc.language.isoen
dc.pagina.final1140
dc.pagina.inicio1136
dc.revistaDigestive diseases and sciences
dc.rightsacceso restringido
dc.subjectnonalcoholic fatty liver
dc.subjectsteatohepatitis
dc.subjectfatty liver
dc.subjectintestinal bacterial overgrowth
dc.subjectanti-endotoxin antibodies
dc.subjectEndoCAb
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleIncreased orocecal transit time in patients with nonalcoholic fatty liver disease
dc.typeartículo
dc.volumen50
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas